ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias

References

• Conte M, Altucci L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res 2012; 18:5526-34; PMID:22904103; http://dx.doi.org/10.1158/1078-0432.CCR-12-2037
   PubMed Web of Science ®Google Scholar
• Benedetti R, Conte M, Altucci L. Targeting histone deacetylases in diseases: where are we? Antioxid Redox Signal 2014; [Epub ahead of print]; PMID:24382114
   PubMedGoogle Scholar
• Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325:834-40; PMID:19608861; http://dx.doi.org/10.1126/science.1175371
   PubMed Web of Science ®Google Scholar
• Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014; 88:1651-68; PMID:25085708; http://dx.doi.org/10.1007/s00204-014-1315-6
   PubMed Web of Science ®Google Scholar
• Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009; 41:199-213; PMID:18790076; http://dx.doi.org/10.1016/j.biocel.2008.08.020
   PubMed Web of Science ®Google Scholar
• Deplus R, Blanchon L, Rajavelu A, Boukaba A, Defrance M, Luciani J, Rothe F, Dedeurwaerder S, Denis H, Brinkman AB, et al. Regulation of DNA Methylation Patterns by CK2-Mediated Phosphorylation of Dnmt3a. Cell Rep 2014; 8:743-53; PMID:25066127; http://dx.doi.org/10.1016/j.celrep.2014.06.048
   PubMed Web of Science ®Google Scholar
• Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 2014; 124:56-63; PMID:24382390; http://dx.doi.org/10.1172/JCI69736
   PubMed Web of Science ®Google Scholar
• Campbell HS, Hall AE, Sanson-Fisher RW, Barker D, Turner D, Taylor-Brown J. Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS). Support Care Cancer 2014; 22:1071-9; PMID:24292016; http://dx.doi.org/10.1007/s00520-013-2061-7
   PubMed Web of Science ®Google Scholar
• Treppendahl MB, Kristensen LS, Gronbaek K. Predicting response to epigenetic therapy. J Clin Invest 2014; 124:47-55; PMID:24382389; http://dx.doi.org/10.1172/JCI69737
   PubMed Web of Science ®Google Scholar
• Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, et al. Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012; 120:3058-68; PMID:22923494; http://dx.doi.org/10.1182/blood-2011-10-386086
   PubMed Web of Science ®Google Scholar
• Saeed S, Logie C, Stunnenberg HG, Martens JH. Genome-wide functions of PML-RARalpha in acute promyelocytic leukaemia. Br J Cancer 2011; 104:554-8; PMID:21245861; http://dx.doi.org/10.1038/sj.bjc.6606095
   PubMed Web of Science ®Google Scholar
• Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, Stunnenberg HG. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 2010; 17:173-85; PMID:20159609; http://dx.doi.org/10.1016/j.ccr.2009.12.042
   PubMed Web of Science ®Google Scholar
• De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Francoijs KJ, Ablain J, Valente S, Castellano R, et al. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 2014; 74:2328-39; PMID:24566867
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J 2014; 4:e170; PMID:24413064
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic' drugs: an update. Mol Oncol 2012; 6:657-82; PMID:23103179; http://dx.doi.org/10.1016/j.molonc.2012.09.004
   PubMed Web of Science ®Google Scholar
• Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007; 17:195-211; PMID:17325692
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-6; PMID:10922406; http://dx.doi.org/10.1093/jnci/92.15.1210
   PubMed Web of Science ®Google Scholar
• Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 2002; 16:1587-609; PMID:12101119; http://dx.doi.org/10.1101/gad.1003302
   PubMed Web of Science ®Google Scholar
• Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000; 103:227-38; PMID:11057896; http://dx.doi.org/10.1016/S0092-8674(00)00115-X
   PubMed Web of Science ®Google Scholar
• Hall A. G proteins and small GTPases: distant relatives keep in touch. Science 1998; 280:2074-5; PMID:9669963; http://dx.doi.org/10.1126/science.280.5372.2074
   PubMed Web of Science ®Google Scholar
• Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21:247-69; PMID:16212495; http://dx.doi.org/10.1146/annurev.cellbio.21.020604.150721
   PubMed Web of Science ®Google Scholar
• Hall A. Rho family GTPases. Biochem Soc Trans 2012; 40:1378-82; PMID:23176484
   PubMed Web of Science ®Google Scholar
• Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004; 265:23-32; PMID:14697350; http://dx.doi.org/10.1016/j.ydbio.2003.06.003
   PubMed Web of Science ®Google Scholar
• Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629-35; PMID:12478284; http://dx.doi.org/10.1038/nature01148
   PubMed Web of Science ®Google Scholar
• Barrio-Real L, Kazanietz MG. Rho GEFs and cancer: linking gene expression and metastatic dissemination. Sci Signal 2012; 5:pe43; PMID:23033535
   PubMed Web of Science ®Google Scholar
• Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010; 115:936-47; PMID:19965643; http://dx.doi.org/10.1182/blood-2009-09-198127
   PubMed Web of Science ®Google Scholar
• Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9:690-701; PMID:18719708; http://dx.doi.org/10.1038/nrm2476
   PubMed Web of Science ®Google Scholar
• Garcia-Mata R, Burridge K. Catching a GEF by its tail. Trends Cell Biol 2007; 17:36-43; PMID:17126549; http://dx.doi.org/10.1016/j.tcb.2006.11.004
   PubMed Web of Science ®Google Scholar
• Arthur WT, Ellerbroek SM, Der CJ, Burridge K, Wennerberg K. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J Biol Chem 2002; 277:42964-72; PMID:12221096; http://dx.doi.org/10.1074/jbc.M207401200
   PubMed Web of Science ®Google Scholar
• Serbanovic-Canic J, Cvejic A, Soranzo N, Stemple DL, Ouwehand WH, Freson K. Silencing of RhoA nucleotide exchange factor, ARHGEF3, reveals its unexpected role in iron uptake. Blood 2011; 118:4967-76; PMID:21715309; http://dx.doi.org/10.1182/blood-2011-02-337295
   PubMed Web of Science ®Google Scholar
• Mullin BH, Prince RL, Dick IM, Hart DJ, Spector TD, Dudbridge F, Wilson SG. Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis. Am J Hum Genet 2008; 82:1262-9; PMID:18499081; http://dx.doi.org/10.1016/j.ajhg.2008.04.016
   PubMed Web of Science ®Google Scholar
• Ling L, Lobie PE. RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem 2004; 279:32737-50; PMID:15102857; http://dx.doi.org/10.1074/jbc.M400601200
   PubMed Web of Science ®Google Scholar
• Kurokawa K, Nakamura T, Aoki K, Matsuda M. Mechanism and role of localized activation of Rho-family GTPases in growth factor-stimulated fibroblasts and neuronal cells. Biochem Soc Trans 2005; 33:631-4; PMID:16042560; http://dx.doi.org/10.1042/BST0330631
   PubMed Web of Science ®Google Scholar
• Kurokawa K, Matsuda M. Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Biol Cell 2005; 16:4294-303; PMID:15987744; http://dx.doi.org/10.1091/mbc.E04-12-1076
   PubMed Web of Science ®Google Scholar
• Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81:1137-46; PMID:7600581; http://dx.doi.org/10.1016/S0092-8674(05)80018-2
   PubMed Web of Science ®Google Scholar
• Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995; 81:1147-57; PMID:7600582; http://dx.doi.org/10.1016/S0092-8674(05)80019-4
   PubMed Web of Science ®Google Scholar
• Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 2005; 8:34-42; PMID:15608632; http://dx.doi.org/10.1038/nn1374
   PubMed Web of Science ®Google Scholar
• Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 1995; 270:23934-6; PMID:7592586; http://dx.doi.org/10.1074/jbc.270.41.23934
   PubMed Web of Science ®Google Scholar
• Kant S, Swat W, Zhang S, Zhang ZY, Neel BG, Flavell RA, Davis RJ. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 2011; 25:2069-78; PMID:21979919; http://dx.doi.org/10.1101/gad.17224711
   PubMed Web of Science ®Google Scholar
• Reif K, Cantrell DA. Networking Rho family GTPases in lymphocytes. Immunity 1998; 8:395-401; PMID:9586630; http://dx.doi.org/10.1016/S1074-7613(00)80545-2
   PubMed Web of Science ®Google Scholar
• Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270:16483-6; PMID:7622446
   PubMed Web of Science ®Google Scholar
• Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 1994; 371:171-5; PMID:8072547; http://dx.doi.org/10.1038/371171a0
   PubMed Web of Science ®Google Scholar
• Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM, Kong AN. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 2001; 60:217-24; PMID:11408617
   PubMed Web of Science ®Google Scholar
• Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993; 73:381-93; PMID:8386592; http://dx.doi.org/10.1016/0092-8674(93)90237-K
   PubMed Web of Science ®Google Scholar
• Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995; 269:403-7; PMID:7618106; http://dx.doi.org/10.1126/science.7618106
   PubMed Web of Science ®Google Scholar
• Spencer JA, Misra RP. Expression of the serum response factor gene is regulated by serum response factor binding sites. J Biol Chem 1996; 271:16535-43; PMID:8663310; http://dx.doi.org/10.1074/jbc.271.28.16535
   PubMed Web of Science ®Google Scholar
• Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004; 14:29-41; PMID:15068801; http://dx.doi.org/10.1016/S1097-2765(04)00153-4
   PubMed Web of Science ®Google Scholar
• Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22:50-5; PMID:22402447; http://dx.doi.org/10.1016/j.gde.2012.02.008
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
   PubMed Web of Science ®Google Scholar
• Simo-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol 2014; [Epub ahead of print]; PMID:25039449; http://dx.doi.org/10.1111/bph.12844
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9; PMID:21386836; http://dx.doi.org/10.1038/nm.2305
   PubMed Web of Science ®Google Scholar
• Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, et al. Relationship between genome and epigenome–challenges and requirements for future research. BMC Genomics 2014; 15:487; PMID:24942464; http://dx.doi.org/10.1186/1471-2164-15-487
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13(9):673-91; PMID:25131830; http://dx.doi.org/10.1038/nrd4360
   PubMed Web of Science ®Google Scholar
• Bravo GM, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 2014; [Epub ahead of print]; PMID:25142817; http://dx.doi.org/10.1038/leu.2014.244
   PubMed Web of Science ®Google Scholar
• Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 2014; 5(16):6558-72; PMID:25115382
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93; PMID:11902573; http://dx.doi.org/10.1038/35106036
   PubMed Web of Science ®Google Scholar
• Mai A, Jelicic K, Rotili D, Di Noia A, Alfani E, Valente S, Altucci L, Nebbioso A, Massa S, Galanello R, et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol 2007; 72:1111-23; PMID:17666592; http://dx.doi.org/10.1124/mol.107.036772
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013; 504:138-42; PMID:24185007; http://dx.doi.org/10.1038/nature12688
   PubMed Web of Science ®Google Scholar
• Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547-8; PMID:18467348; http://dx.doi.org/10.1093/bioinformatics/btn224
   PubMed Web of Science ®Google Scholar
• Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 2001; 17:509-19; PMID:11395427; http://dx.doi.org/10.1093/bioinformatics/17.6.509
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature medicine 2005; 11:77-84; PMID:15619633; http://dx.doi.org/10.1038/nm1161
   PubMed Web of Science ®Google Scholar